"As we optimize and test our stem cell-based therapeutic platforms, RayBiotech's biomarker analysis services, products and technologies have enabled us to streamline our biochemical data analysis strategy, providing broad coverage of biomarker assessment in a variety of applications and scenarios." said Dr. Alexa Poole, Senior Scientist at California Stem Cell.
"California Stem Cell is at the forefront of the stem cell therapeutics industry. We applaud their efforts to develop stem cell-based therapeutics and are pleased that RayBiotech's antibody array and ELISA biomarker characterization technologies suit the needs of researchers and scientists at CSC. We also congratulate California Stem Cell on their recent FDA approval to enter Phase III clinical trials for stem cell-based treatment of metastatic melanoma. It is with great satisfaction that we are able to provide CSC with biomarker characterization technologies for this and other therapeutic endeavors." commened on the agreement, RayBiotech's President, Chief Operating Officer and Co-founder, Ms. Rani Huang, stated.